Tscan therapeutics reports second quarter 2025 financial results and provides corporate update

Two-year relapse data from alloha™ phase 1 heme trial to be presented by end of year expects to dose first solid tumor patients with multiplex tcr-t in the third quarter of 2025 cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 waltham, mass., aug. 12, 2025 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biotechnology company focused on the development of t cell receptor (tcr)-engineered t cell (tcr-t) therapies for the treatment of patients with cancer, today reported financial results for the second quarter ended june 30, 2025, and provided a corporate update.
TCRX Ratings Summary
TCRX Quant Ranking